Company
Team
CORPORATE GOVERNANCE
Platforms
Glycovirology
Diseases and Therapies Overview
pipeline
ProLectin Pipeline
Degenerative Disease pipeline
Resources
IN THE NEWS
Articles
Stroke video
faq
SCIENTIFIC PUBLICATIONS
investors
Company presentation
press releases
Research
financial
Contact US
$BIXT
Company
Platforms
Glycovirology
Diseases and Therapies Overview
Resources
Investors
Pipeline
contact us
Sitemap
Pages
Home
About BioxyTran
Company
Investor Relations
Resources
Contact
Team
Pipeline
Company
Governance
Glycovirology
Diseases and Therapies
Glycovirology Scientific Publications
Hypoxia and Degenerative Diseases Publications
Degenerative Diseases Publications
NASH Publications
Heart Failure Publications
Glycovirology Publications
Introducing BXT-25
Kidney Fibrosis
Chronic Kidney Disease
Autism Spectrum Disorder
BXT-25
Press Releases
Bioxytran Highlights Advances in Real-Time Tissue Oxygenation Mapping Relevant to Investigational Oxygen Therapeutic BXT-25
Bioxytran Highlights Newly Published Research on Real-Time Tissue Oxygenation Monitoring Relevant to BXT-25 Development
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission Copy
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
Bioxytran’s Medical Breakthrough in Fighting All Viruses
Bioxytran Measures the Presence of Carbon Monoxide When BXT-25 Delivers Oxygen to the Brain
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
Bioxytran Announces Dr. Milanova Appointed to Board of Directors
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
Bioxytran Interview at the Emerging Growth Conference
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
Bioxytran Interview at the Emerging Growth Conference
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
Bioxytran Interview at the Emerging Growth Conference
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv
Bioxytran Interview at the Emerging Growth Conference - Wednesday August 17th, 2022 @ 12PM EST
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
Bioxytran Published A Surrogate Marker for ARDS and Stroke Patients
Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
Bioxytran Guest Speaker on Perfusionists Continuing Education Program Discussing Acute Respiratory Distress Syndrome and Ways to Combat COVID-19
Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
Bioxytran Unveiling Concept of a new Vital Sign at Targeting Mitochondria World Congress
Latest Nobel Prize Validates Bioxytran at the Forefront of Scientific Discovery
Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board
Bioxytran Inc. Announces Appointment of Dr. Hana Chen-Walden to Scientific Advisory Board
Bioxytran Inc. Appoints Cynthia Ekberg Tsai to Company Advisory Board
Bioxytran Inc. Bolsters Advisory Board with Addition of Veteran Financial Advisor Jonathan Barkman
Avise Analytics Initiates Coverage on Bioxytran Inc.
Bioxytran Inc. Invited to New York Venture Summit
Bioxytran's Mdx Viewer Demonstrates Early Warning Signs of Brain Health During Cardiovascular Surgeries
Bioxytran Now Using Paradigm Changing Vital Sign That Can Measure Real-Time Tissue Oxygen Balance in Emergency Medicine
Bioxytran, Inc. Announces Public Company Executive Steve Aust to Join Advisory Board
Posts
What Are the 4 Stages of Cirrhosis of the Liver? Symptoms, Life Expectancy & End-Stage Warning Signs
What Is a Stroke? Symptoms, Causes, Mini Stroke Signs & Prevention
What Is NASH Disease? Causes, Symptoms, Stages & How Nonalcoholic Steatohepatitis Leads to Cirrhosis
Hyperparathyroidism Treatment: Diagnosis, PTH Levels, Medications & Diet Explained
Liver Fibrosis Explained: Symptoms, Causes, Stages & Emerging Treatment Research
What Are Chronic Kidney Diseases? Symptoms, Causes, and Latest Treatments
Bioxtyran (OTCMKTS: BIXT) Licenses Phase 2 Asset for COVID-19 Patients After Finding Smoking Gun Journal Article
BXT-25: A New Solution for Late Stage Treatment of Wuhan Coronavirus
Scientific Background: How cells sense and adapt to oxygen availability
Bioxytran’s Tissue Oxygenation Therapy Breaking the Stroke Paradigm
The Pressure is On: Following New Blood Pressure Guidelines Could Prevent Death Among Stroke Survivors
Mothers-To-Be: Due Date Soon? Look Out for Infections
Scientific Publications
Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients
An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
Chemokines modulate glycan binding and the immunoregulatory activity of galectins
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance
The Two Nobel Prize Investment
Galectin approach to lower covid transmission - Drug Development for clinical use
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure
Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial
Assessment of Galectin-1, Galectin-3, and PGE2 Levels in Patients with COVID-19
Molecular, Cell and Tissue Studies of Galectin-3:CD98 Interactions in IPF and COVID Pneumonitis
Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites
SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection
Identification of lectin receptors for conservedSARS-CoV-2 glycosylation sites
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
Acute hantavirus infection induces galectin-3-binding protein
Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation In Airway Epithelial Cells
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
Serum Galectin-3 and Aldosterone: potential biomarkers of cardiac complications in patients with COVID-19
Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients.
Immunopathology of galectin-3: an increasingly promising target in COVID-19
Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studies
Dr. Nambier on the Development of Galectin-1 for Head and Neck Cancer
Galectins in tumour immunity
Galectin proteins defend against bacterial wolves in sheeps' clothing
Galectin 3: The "Protein of Death's" Crazy Life
Galectin Inhibitors, Viral Infections, Inflammation
The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
Perfluorocarbons Enhance a T2*-Based MRI Technique for Identifying the Penumbra in a Rat Model of Acute Ischemic Stroke
Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial
Dose-Dependent Hemodynamic, Biochemical, and Tissue Oxygen Effects of OC99 following Severe Oxygen Debt Produced by Hemorrhagic Shock in Dogs
Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Cell entry mechanisms of SARS-CoV-2
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic
Gal power: the diverse roles of galectins in regulating viral infections
Galectin-3 Exerts Cytokine-Like Regulatory Actions through the JAK–STAT Pathway
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients
Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections
Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1*
Galectin-1 Binds to Influenza Virus and Ameliorates Influenza Virus Pathogenesis
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure
Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies
Galectin-9 Regulates The Threshold of B Cell Activation and Autoimmunity
Computational Study of Potential Galectin-3 Inhibitors in the Treatment of COVID-19
Identification of lectin recept ors for conservedSARS-CoV-2 glycosylation sites
Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
Potential Role of Galectin-glycan Lattices in SARS-CoV-2 Infection and Pathogenesis: A Hypothesis
The role of galectins in virus infection - A systemic literature review
Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider
A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
A potential role for Galectin-3 inhibitors in the treatment of COVID-19
Roles of galectins in infection
Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial